Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Providing a comprehensive evaluation for hereditary colon cancer in patients with a personal or family history suggestive of a hereditary colon cancer syndrome
Serving as a second-tier test for patients in whom previous targeted gene variant analyses for specific hereditary colorectal cancer-related genes were negative
Establishing a diagnosis of a hereditary colon cancer syndrome in some cases, allowing for targeted cancer surveillance of associated extra-colonic organs known to be at increased risk for cancer
Identifying variants within genes known to be associated with increased risk for colon cancer allowing for predictive testing of at-risk family members
This test includes next-generation sequencing, Sanger sequencing, array comparative genomic hybridization, and multiplex ligation-dependent probe amplification to evaluate for the genes listed on the panel.
Prior Authorization is available for this assay; see Special Instructions
See Targeted Gene Regions Interrogated by Hereditary Colon Cancer Panel in Special Instructions for details regarding the targeted gene regions identified by this test.
The following algorithms are available in Special Instructions:
Custom Sequence Capture and Targeted Next-Generation Sequencing Followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Multiplex Ligation-Dependent Probe Amplification (MLPA)